337 related articles for article (PubMed ID: 24016461)
1. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma.
Casucci M; Nicolis di Robilant B; Falcone L; Camisa B; Norelli M; Genovese P; Gentner B; Gullotta F; Ponzoni M; Bernardi M; Marcatti M; Saudemont A; Bordignon C; Savoldo B; Ciceri F; Naldini L; Dotti G; Bonini C; Bondanza A
Blood; 2013 Nov; 122(20):3461-72. PubMed ID: 24016461
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells.
Schmueck-Henneresse M; Omer B; Shum T; Tashiro H; Mamonkin M; Lapteva N; Sharma S; Rollins L; Dotti G; Reinke P; Volk HD; Rooney CM
J Immunol; 2017 Jul; 199(1):348-362. PubMed ID: 28550199
[TBL] [Abstract][Full Text] [Related]
3. Conjugation of TLR7 Agonist Combined with Demethylation Treatment Improves Whole-Cell Tumor Vaccine Potency in Acute Myeloid Leukemia.
Zhong G; Jin G; Zeng W; Yu C; Li Y; Zhou J; Zhang L; Yu L
Int J Med Sci; 2020; 17(15):2346-2356. PubMed ID: 32922200
[No Abstract] [Full Text] [Related]
4. CD44v6: a target for antibody-based cancer therapy.
Heider KH; Kuthan H; Stehle G; Munzert G
Cancer Immunol Immunother; 2004 Jul; 53(7):567-79. PubMed ID: 14762695
[TBL] [Abstract][Full Text] [Related]
5. Valrubicin-loaded immunoliposomes for specific vesicle-mediated cell death in the treatment of hematological cancers.
Georgievski A; Bellaye PS; Tournier B; Choubley H; Pais de Barros JP; Herbst M; Béduneau A; Callier P; Collin B; Végran F; Ballerini P; Garrido C; Quéré R
Cell Death Dis; 2024 May; 15(5):328. PubMed ID: 38734740
[TBL] [Abstract][Full Text] [Related]
6. Cysteine-binding adjuvant enhances survival and promotes immune function in a murine model of acute myeloid leukemia.
Slezak AJ; Chang K; Beckman TN; Refvik KC; Alpar AT; Lauterbach AL; Solanki A; Kwon JW; Gomes S; Mansurov A; Hubbell JA
Blood Adv; 2024 Apr; 8(7):1747-1759. PubMed ID: 38324726
[TBL] [Abstract][Full Text] [Related]
7. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.
Gill S; Tasian SK; Ruella M; Shestova O; Li Y; Porter DL; Carroll M; Danet-Desnoyers G; Scholler J; Grupp SA; June CH; Kalos M
Blood; 2014 Apr; 123(15):2343-54. PubMed ID: 24596416
[TBL] [Abstract][Full Text] [Related]
8. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.
Kenderian SS; Ruella M; Shestova O; Klichinsky M; Aikawa V; Morrissette JJ; Scholler J; Song D; Porter DL; Carroll M; June CH; Gill S
Leukemia; 2015 Aug; 29(8):1637-47. PubMed ID: 25721896
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo.
Pizzitola I; Anjos-Afonso F; Rouault-Pierre K; Lassailly F; Tettamanti S; Spinelli O; Biondi A; Biagi E; Bonnet D
Leukemia; 2014 Aug; 28(8):1596-605. PubMed ID: 24504024
[TBL] [Abstract][Full Text] [Related]
10. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.
Mardiros A; Dos Santos C; McDonald T; Brown CE; Wang X; Budde LE; Hoffman L; Aguilar B; Chang WC; Bretzlaff W; Chang B; Jonnalagadda M; Starr R; Ostberg JR; Jensen MC; Bhatia R; Forman SJ
Blood; 2013 Oct; 122(18):3138-48. PubMed ID: 24030378
[TBL] [Abstract][Full Text] [Related]
11. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis.
Todaro M; Gaggianesi M; Catalano V; Benfante A; Iovino F; Biffoni M; Apuzzo T; Sperduti I; Volpe S; Cocorullo G; Gulotta G; Dieli F; De Maria R; Stassi G
Cell Stem Cell; 2014 Mar; 14(3):342-56. PubMed ID: 24607406
[TBL] [Abstract][Full Text] [Related]
12. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.
Long AH; Haso WM; Shern JF; Wanhainen KM; Murgai M; Ingaramo M; Smith JP; Walker AJ; Kohler ME; Venkateshwara VR; Kaplan RN; Patterson GH; Fry TJ; Orentas RJ; Mackall CL
Nat Med; 2015 Jun; 21(6):581-90. PubMed ID: 25939063
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor T cell therapy in AML: How close are we?
Gill S
Best Pract Res Clin Haematol; 2016 Dec; 29(4):329-333. PubMed ID: 27890255
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
15. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
Lee DW; Kochenderfer JN; Stetler-Stevenson M; Cui YK; Delbrook C; Feldman SA; Fry TJ; Orentas R; Sabatino M; Shah NN; Steinberg SM; Stroncek D; Tschernia N; Yuan C; Zhang H; Zhang L; Rosenberg SA; Wayne AS; Mackall CL
Lancet; 2015 Feb; 385(9967):517-528. PubMed ID: 25319501
[TBL] [Abstract][Full Text] [Related]
16. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.
Hudecek M; Sommermeyer D; Kosasih PL; Silva-Benedict A; Liu L; Rader C; Jensen MC; Riddell SR
Cancer Immunol Res; 2015 Feb; 3(2):125-35. PubMed ID: 25212991
[TBL] [Abstract][Full Text] [Related]
17. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.
Maude SL; Teachey DT; Porter DL; Grupp SA
Blood; 2015 Jun; 125(26):4017-23. PubMed ID: 25999455
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy with chimeric antigen receptors for multiple myeloma.
Garfall AL; Fraietta JA; Maus MV
Discov Med; 2014 Jan; 17(91):37-46. PubMed ID: 24411699
[TBL] [Abstract][Full Text] [Related]
19. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.
Turtle CJ; Hanafi LA; Berger C; Gooley TA; Cherian S; Hudecek M; Sommermeyer D; Melville K; Pender B; Budiarto TM; Robinson E; Steevens NN; Chaney C; Soma L; Chen X; Yeung C; Wood B; Li D; Cao J; Heimfeld S; Jensen MC; Riddell SR; Maloney DG
J Clin Invest; 2016 Jun; 126(6):2123-38. PubMed ID: 27111235
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
Kochenderfer JN; Dudley ME; Kassim SH; Somerville RP; Carpenter RO; Stetler-Stevenson M; Yang JC; Phan GQ; Hughes MS; Sherry RM; Raffeld M; Feldman S; Lu L; Li YF; Ngo LT; Goy A; Feldman T; Spaner DE; Wang ML; Chen CC; Kranick SM; Nath A; Nathan DA; Morton KE; Toomey MA; Rosenberg SA
J Clin Oncol; 2015 Feb; 33(6):540-9. PubMed ID: 25154820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]